Sunesis Pharmaceuticals to Host Conference Call on May 8th to Discuss First Quarter 2019 Financial Results and Recent Highlig...
May 01 2019 - 7:00AM
Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that
it will host a conference call on Wednesday, May 8th, 2019 at 4:30
p.m. Eastern Time to discuss corporate updates and financial
results for the first quarter ended March 31, 2019.
The call can be accessed by dialing (844) 296-7720 (U.S. and
Canada) or (574) 990-1148 (International) and entering passcode
1396684.
To access the live audio webcast, or the subsequent archived
recording, visit the "Investors and Media - Calendar of Events"
section of the Sunesis website at http://ir.sunesis.com. The
webcast will be recorded and available for replay on the company's
website for two weeks.
About Sunesis
Pharmaceuticals
Sunesis is a biopharmaceutical company
developing new therapeutics for the treatment of hematologic and
solid cancers. Sunesis has built an experienced drug development
organization committed to improving the lives of people with
cancer. The Company is focused on advancing its novel kinase
inhibitor pipeline, with an emphasis on its oral non-covalent BTK
inhibitor vecabrutinib. Vecabrutinib is currently being evaluated
in a Phase 1b/2 study in adults with chronic lymphocytic leukemia
and other B-cell malignancies that have progressed after prior
therapies. The Company’s proprietary PDK1 inhibitor SNS-510 is in
preclinical development. PDK1 is a master kinase that activates
other kinases important to cell growth and survival including
members of the AKT, PKC, RSK, and SGK families. Sunesis is
exploring strategic alternatives for vosaroxin, a late-stage
investigational product for relapsed or refractory AML. Sunesis
also has an interest in the pan-RAF inhibitor TAK-580 which is
licensed to Takeda. TAK-580 is in a clinical trial for pediatric
low-grade glioma.
For additional information on Sunesis, please
visit www.sunesis.com.
SUNESIS and the logos are trademarks of Sunesis
Pharmaceuticals, Inc.
Investor and Media
Inquiries:Maeve ConneightonArgot Partners212-600-1902 |
Willie
QuinnSunesis Pharmaceuticals Inc.650-266-3716 |
Sunesis Pharmaceuticals (NASDAQ:SNSS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Sunesis Pharmaceuticals (NASDAQ:SNSS)
Historical Stock Chart
From Sep 2023 to Sep 2024